Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer

E Vjaters; K Fizazi; ND James; TL Tammela; N Matsubara; Priou; P Beuzeboc; T Lesimple; P Bono; V Kataja; JA Garcia; A Protheroe; J Aspegren; H Joensuu; I Kuss; S Thiele; S Fiala-Buskies; RH Jones

doi:10.1016/S0302-2838(22)00606-6

Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer

E Vjaters, K Fizazi, ND James, TL Tammela, N Matsubara, Priou, P Beuzeboc, T Lesimple, P Bono, V Kataja, JA Garcia, A Protheroe, J Aspegren, H Joensuu, I Kuss, S Thiele, S Fiala-Buskies, RH Jones

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	A0523
Pages (from-to)	S786-S787
Number of pages	2
Journal	European Urology
Volume	81
Issue number	Suppl.1
DOIs	https://doi.org/10.1016/S0302-2838(22)00606-6
Publication status	Published - Feb 2022
Externally published	Yes
Event	37th Annual European Association of Urology (EAU) Congress - Amsterdam, Netherlands Duration: 1 Jul 2022 → 4 Jul 2022 Conference number: 37 https://resource-centre.uroweb.org/resource-centre/eau22

Field of Science*

3.1 Basic medicine
3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0302-2838(22)00606-6

https://www.europeanurology.com/article/S0302-2838(22)00606-6/fulltext

Cite this

Vjaters, E., Fizazi, K., James, ND., Tammela, TL., Matsubara, N., Priou, Beuzeboc, P., Lesimple, T., Bono, P., Kataja, V., Garcia, JA., Protheroe, A., Aspegren, J., Joensuu, H., Kuss, I., Thiele, S., Fiala-Buskies, S., & Jones, RH. (2022). Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer. European Urology, 81(Suppl.1), S786-S787. Article A0523. https://doi.org/10.1016/S0302-2838(22)00606-6

@article{a45b92d18e8c4ecb8d86eddcf73e627d,

title = "Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer",

author = "E Vjaters and K Fizazi and ND James and TL Tammela and N Matsubara and Priou and P Beuzeboc and T Lesimple and P Bono and V Kataja and JA Garcia and A Protheroe and J Aspegren and H Joensuu and I Kuss and S Thiele and S Fiala-Buskies and RH Jones",

year = "2022",

month = feb,

doi = "10.1016/S0302-2838(22)00606-6",

language = "English",

volume = "81",

pages = "S786--S787",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "Suppl.1",

note = "37th Annual European Association of Urology (EAU) Congress, EAU 2022, EAU22 ; Conference date: 01-07-2022 Through 04-07-2022",

url = "https://resource-centre.uroweb.org/resource-centre/eau22",

}

Vjaters, E, Fizazi, K, James, ND, Tammela, TL, Matsubara, N, Priou, Beuzeboc, P, Lesimple, T, Bono, P, Kataja, V, Garcia, JA, Protheroe, A, Aspegren, J, Joensuu, H, Kuss, I, Thiele, S, Fiala-Buskies, S & Jones, RH 2022, 'Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer', European Urology, vol. 81, no. Suppl.1, A0523, pp. S786-S787. https://doi.org/10.1016/S0302-2838(22)00606-6

TY - JOUR

T1 - Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer

AU - Vjaters, E

AU - Fizazi, K

AU - James, ND

AU - Tammela, TL

AU - Matsubara, N

AU - Priou, null

AU - Beuzeboc, P

AU - Lesimple, T

AU - Bono, P

AU - Kataja, V

AU - Garcia, JA

AU - Protheroe, A

AU - Aspegren, J

AU - Joensuu, H

AU - Kuss, I

AU - Thiele, S

AU - Fiala-Buskies, S

AU - Jones, RH

N1 - Conference code: 37

PY - 2022/2

Y1 - 2022/2

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=rsu_pure_&SrcAuth=WosAPI&KeyUT=WOS:000812320400517&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1016/S0302-2838(22)00606-6

DO - 10.1016/S0302-2838(22)00606-6

M3 - Meeting Abstract

SN - 0302-2838

VL - 81

SP - S786-S787

JO - European Urology

JF - European Urology

IS - Suppl.1

M1 - A0523

T2 - 37th Annual European Association of Urology (EAU) Congress

Y2 - 1 July 2022 through 4 July 2022

ER -

Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer

Field of Science*

Publication Type*

UN SDGs

Access to Document

Other files and links

Cite this